Skip to main content
SteadySharesSteadySharesSteadyStShares
The market
MarketsDiscover
Follow the money
Super InvestorsPolitician TradesCrypto Desk
Yours
My WealthNews
Settings Sign in to save your work
Pre-market
SteadySharesMarketsDiscoverSuper InvestorsMy WealthPoliticiansCryptoNews
DiscoverMXCT
HealthcareNMSUSD

MaxCyte, Inc.

$00123456789.0012345678900123456789-3.6%
52w low (est.) $0.82$1.41 52w high (est.)
Market data · updated 1h ago
Market data
Market cap
USD125.33M
52w range
USD0.64 - USD2.31
Beta
1.66
Sector
Healthcare
Data quality
83/100
Valuation
DCF fair value
USD1.57
Margin of safety
+45.4%
Quality & efficiency
Moat score
35/100
Return on equity
-21.3%
Profit margin
-121.2%
Debt / equity
0.10
Growth & analysts
Revenue growth
-7.1%
Analyst target
USD4.11
Target upside
+280.3%
Analysts
4
Run the 10-point checklist before you buy How these numbers are made

About MaxCyte, Inc.

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

Valuation

ValueGrowthProfitHealthIncome42QUALITY
Overall Rating
52
Hold
Hold

Derived from filed metrics · High confidence (83% of the inputs available)

Moat Score35
DCF Intrinsic Value
USD1.57+45.4% upside

Moat, DCF and rating computed by our valuation engine (ported from the original Python model).

Fundamentals

Market Cap
USD125.33M
P/E Ratio
N/A
Dividend Yield
0.00%
Revenue Growth
-7.1%
Profit Margin
-121.2%
ROE
-21.3%
Debt / Equity
0.10
Beta
1.66
Beaten Down
vs Healthcare sector:Moat 35 vs 7Yield 0.00% vs 0.3%

Statistics

Similar Stocks · Healthcare

LLY73
$920.00+0.7%
AZN.L72
£105.20+0.6%
UNH71
$492.10+1.6%
JNJ70
$146.20-0.2%

Latest News · MXCT